Target intelligence / Profile preview

Cytochrome bcc-aa3 oxidase subunit QcrB (QcrB)

Target
QcrB
Molecular classification
Enzyme (specifically, part of the cytochrome bc1 (bcc) complex, a respiratory oxidoreductase), Component of the cytochrome bcc-aa3 respiratory supercomplex
01

Overview

Cytochrome bcc-aa3 oxidase subunit QcrB is the major redox-active subunit of the mycobacterial cytochrome bcc complex, part of the larger bcc-aa3 supercomplex crucial for aerobic respiration in mycobacteria such as *M. tuberculosis*. QcrB spans the membrane, binding two hemes (bH and bL), and constitutes the site where menaquinol oxidation initiates electron transfer to the respiratory chain, ultimately reducing molecular oxygen via the associated aa3-type oxidase domain. These reactions maintain the proton motive force for ATP synthesis. Selective inhibition of QcrB by small-molecule drugs (such as Q203) blocks this energy metabolism, leading to bactericidal effects. QcrB is structurally distinct from human mitochondrial complexes, making it an attractive target for antimicrobial drug development, particularly for drug-resistant tuberculosis

Other names
Cytochrome b subunit QcrBQcrB subunitMycobacterial cytochrome bCytochrome b bcc complex componentbc1 complex subunit QcrBbc complex subunit QcrB
02

Mechanism of action

Competitive inhibition of the Qp (menaquinol binding) site, preventing electron transfer to heme cofactors, halting respiratory ATP production, and thereby killing or stunting the proliferation of mycobacteria

03

Biological functions

Electron transportCellular respiration (aerobic energy metabolism)Maintenance of proton motive forceATP production in the bacterial respiratory chain
04

Disease associations

Infection (principal target in tuberculosis and potentially in other mycobacterial diseases)Other (general pathogen survival)
05

Safety considerations

Off-target toxicity risk if host mitochondria complexes are affected (however, QcrB is distinct from human homologs, improving selectivity)Potential for development of resistance through target mutations (T313A, and others)Need for combination therapy to prevent resistance and increase efficacy
06

Interacting drugs

Q203 (Telacebec)

3 more in the full profile.

07

Biomarkers

QcrB mutation profile (e.g., T313A confers resistance to Q203)Expression levels of qcrB in pathogenic mycobacteria

Beyond the preview

Go deeper on Cytochrome bcc-aa3 oxidase subunit QcrB (QcrB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome bcc-aa3 oxidase subunit QcrB (QcrB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call